76.14MMarket Cap-0.22P/E (TTM)
0.420High0.381Low6.11MVolume0.420Open0.418Pre Close2.44MTurnover3.16%Turnover RatioLossP/E (Static)194.44MShares3.20052wk High-13.05P/B75.79MFloat Cap0.29052wk Low--Dividend TTM193.54MShs Float152.883Historical High--Div YieldTTM9.29%Amplitude0.290Historical Low0.399Avg Price1Lot Size
bluebird bio Stock Forum
As a result of the reverse split, the new contract multiplier for options will be 100, and the new deliverable per contract will be 5 new bluebird bio common shares. The underlying price for BLUE1 options will be calculated as ...
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
📊⚡️📊
Company Overview
• Founded: 2013
• Founder: Dr. Jonathan Rothberg, a serial entrepreneur also known for inventing next-generation DNA sequencing (NGS).
• Headquarters: Guilford, Connecticut, USA
• ...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Positive
94.7% of evaluable patients achieved complete resolution of severe VOEs
86.8% of evaluable patients achieved complete resolution of VOEs
100% success rate in pediatric patients (10/10) for VOE resolution
No stroke recurrence in patients with prior history through 9 y...
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Sunday, 8th December at 12:30 pm
Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially trans...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
No comment yet